Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success was offset by weaker sales from its medical-surgical business.

Medtronic’s VenaSeal Spectrum postmarket clinical trial program is highlighting the need for further patient-centric ...

We expect Medtronic's new neuromodulation technology, neurovascular devices and insulin pumps, the introduction of pulsed field ablation for the atrial fibrillation market, and transcatheter heart ...

Medtronic PLC (NYSE:MDT) reported its ninth consecutive quarter of mid-single-digit revenue growth, with strong performances in Cardiac Ablation Solutions, Leadless Pacing, Neuromodulation ...

Shares of Medtronic plc (NYSE:MDT – Get Free Report) shot up 0.1% during mid-day trading on Friday following a dividend announcement from the company. The company traded as high as $93.27 and last ...

Cardiac Ablation Solutions: This segment has shown promising growth potential, contributing to the company’s overall performance in the cardiovascular space. 2. Renal denervation: Medtronic is ...

The Global Radiofrequency Ablation Device Market is expected to grow at 9.35% CAGR from 2025 to 2032. The latest Research report published by Coherent Market Insights with the title "An Increase ...

Medtronic plc (NYSE:MDT – Get Free Report) has received a consensus rating of “Hold” from the sixteen ratings firms that are ...

HYDERABAD Feb 25 (Reuters) - Medical device maker Medtronic (MDT.N), opens new tab is looking at options to modify its global manufacturing footprint as part of efforts to mitigate any impact of U ...

Medtronic had a decent quarter, but it was less than the analysts expected. The company's $8.3 billion in net revenue was up 2.5% compared to the prior year, 4.1% organically, driven by strength ...